Matthew J. Goldstein joined Tango Therapeutics as head of immunology in July 2018. Matt brings comprehensive experience in translational research, clinical development and cancer immunotherapy to his role directing the immunology program and overseeing Tango’s partnership with Gilead. Prior to Tango Therapeutics, Matt was a founding member of Neon Therapeutics, a Third Rock Ventures company, where he led translational medicine and early development.
Matt earned his Bachelor of Arts from Swarthmore College, where he graduated with honors, and earned his medical degree and doctorate from Stanford University, where he studied cancer immunology in the lab of Ron Levy. Matt completed his clinical training in internal medicine at Brigham and Women’s Hospital.